Synageva BioPharma Appoints Leading Clinician and Industry Executive, Dr. Mark Goldberg, to Its...

Posted on: Friday, 10 October 2008, 09:00 CDT Synageva BioPharma announced today the appointment of Mark Goldberg, M.D., Senior Vice President of Clinical Research at Genzyme Corp., and a leading medical oncologist and hematologist, to the Company's Board of Directors. "In addition to his accomplished medical background, Mark is a seasoned industry executive and his direct experience in overseeing the development of Genzyme's products will make his strategic guidance an invaluable asset to the Synageva Board," said Felix J. Baker, Ph.D., Chairman of the Synageva Board and Managing Partner at Baker Brothers Investments. "Having worked very closely with Dr Goldberg for almost 10 years at Genzyme, I am confident Mark will provide critical insight into the execution of our clinical development and product commercialization... [read full story]